Cannabis-Based Medical Products Show Sustained Sleep Quality Improvements in 18-Month Insomnia Study
Key Insights
A study published in PLOS Mental Health found that 124 insomnia (search) patients using cannabis-based medical products (search) reported sustained improvements in sleep quality over 18 months of treatment.
Patients also experienced reduced anxiety (search), depression (search), and pain levels, with only 9% reporting mild side effects such as fatigue and dry mouth.
The research provides real-world evidence for cannabis-based therapies as potential alternatives for chronic insomnia (search) when conventional treatments prove ineffective.
A comprehensive 18-month study has demonstrated that cannabis-based medical products (search) may offer sustained relief for patients with chronic insomnia (search), according to research published August 27 in PLOS Mental Health. The study, led by Arushika Aggarwal of Imperial College London and her colleagues, tracked 124 patients prescribed medical cannabis and found consistent improvements in sleep quality throughout the treatment period.
Study Design and Patient Population
The research examined outcomes from patients who were prescribed cannabis-based medical treatments for insomnia (search), monitoring changes in sleep quality, anxiety (search) and depression (search) levels, and overall quality of life across one to 18 months of treatment. Sleep problems affect roughly one in three people, with about 10 percent of adults meeting the criteria for an insomnia disorder, making this research particularly relevant given the limitations of current treatment options.
Sustained Clinical Benefits
Patients consistently reported better sleep throughout the entire 18-month study period. Beyond sleep improvements, participants also noted reduced anxiety (search) and depression (search), along with lower levels of pain. The sustained nature of these benefits suggests that cannabis-based medical products (search) may provide long-term therapeutic value for individuals with chronic sleep difficulties.
"Over an 18-month period, our study showed that treatment for insomnia (search) with cannabis-based medicinal products was associated with sustained improvements in subjective sleep quality and anxiety (search) symptoms," explained co-author Dr. Simon Erridge, Research Director at Curaleaf Clinic (search). "These findings support the potential role of medical cannabis as a medical option where conventional treatments have proven ineffective, though further randomised trials are needed to confirm long-term efficacy."
Safety Profile and Side Effects
The treatment demonstrated a favorable safety profile, with approximately nine percent of patients experiencing side effects such as fatigue, dry mouth, or insomnia (search). Importantly, none of these adverse events were considered serious, contrasting with the dependence risks associated with approved insomnia medications.
Clinical Implications and Future Research
The study addresses a significant unmet medical need, as standard treatment options for insomnia (search) are often difficult to access and carry risks of dependence. The research provides valuable real-world evidence that extends beyond typical short-term clinical trials.
"Conducting this long-term study provided valuable real-world evidence on patient outcomes that go beyond what we typically see in short-term trials," Dr. Erridge noted. "It was particularly interesting to observe signs of potential tolerance over time, which highlights the importance of continued monitoring and individualised treatment plans."
While the results are promising, researchers emphasize that more rigorous randomized controlled trials are required to confirm the safety and effectiveness of cannabis-based medical products (search) for insomnia (search) treatment. The findings suggest these therapies may provide a new therapeutic avenue for improving sleep among people with chronic insomnia, particularly when conventional treatments have proven inadequate.